1. Salbutamol repurposing ameliorates neuromuscular junction defects and muscle atrophy in Col6a1−/− mouse model of collagen VI‐related myopathies.
- Author
-
Calabrò, Sonia, Nogara, Leonardo, Jian, Yongzhi, Valentin, Manuel, Bizzotto, Dario, Braghetta, Paola, Russo, Loris, Gambarotto, Lisa, Blaauw, Bert, Hashemolhosseini, Said, Bonaldo, Paolo, and Cescon, Matilde
- Subjects
CONGENITAL myasthenic syndromes ,SPINAL muscular atrophy ,BECKER muscular dystrophy ,MULTIPLE comparisons (Statistics) ,RESPIRATORY muscles ,FACIOSCAPULOHUMERAL muscular dystrophy - Abstract
This article discusses a study on the potential use of the FDA-approved drug salbutamol for the treatment of collagen VI-related myopathies, a group of progressive muscle disorders. The study, conducted on a mouse model, found that salbutamol administration improved neuromuscular junction defects and muscle atrophy. Salbutamol has previously shown positive effects on neuromuscular junction structure and function in other animal models and has been used successfully off-label in various diseases. The study also found that salbutamol treatment increased muscle mass and promoted muscle regeneration in both the mouse model and wild-type mice. However, the study noted that further research is needed to optimize salbutamol-based therapeutic strategies for clinical trials. The study was funded by various organizations and declared no conflicts of interest. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF